Bluejay Diagnostics (BJDX) FDA Approvals $1.21 -0.24 (-16.55%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$1.22 +0.01 (+0.99%) As of 07/20/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Bluejay Diagnostics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Bluejay Diagnostics (BJDX). Over the past two years, Bluejay Diagnostics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Interleukin-6. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Interleukin-6 FDA Regulatory Events Interleukin-6 is a drug developed by Bluejay Diagnostics for the following indication: In patients diagnosed with sepsis and septic shock. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Enrollment Update - April 7,2026Enrollment Update Drug: Interleukin-6Announced Date: April 7, 2026Indication: In patients diagnosed with sepsis and septic shock.AnnouncementBluejay Diagnostics, Inc. announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring.Read AnnouncementAbstract Presentation - April 15,2025Abstract Presentation Drug: Interleukin-6Announced Date: April 15, 2025Indication: In patients diagnosed with sepsis and septic shock.AnnouncementBluejay Diagnostics, Inc. announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025.AI SummaryBluejay Diagnostics, Inc. announced that an abstract detailing the Symphony IL-6 Test, its lead product candidate, has been accepted for presentation at the SAEM Annual Meeting in Philadelphia from May 13-16, 2025. This abstract is based on the SYMON-I pilot clinical study, which examines the role of interleukin‑6 (IL‑6) in sepsis patients. The study assessed IL‑6 levels as an early indicator to predict 28-day and 7-day mortality rates, as well as microbiological outcomes. The upcoming presentation will allow emergency medicine professionals to gain insights into how the Symphony IL‑6 Test could serve as a valuable tool for early diagnosis and management of sepsis. This development marks a significant step forward in deploying rapid biomarker testing in the clinical setting, aiming to improve patient triage and care in critical situations.Read Announcement Bluejay Diagnostics FDA Events - Frequently Asked Questions Has Bluejay Diagnostics received FDA approval? As of now, Bluejay Diagnostics (BJDX) has not received any FDA approvals for its therapy in the last two years. What drugs has Bluejay Diagnostics submitted to the FDA? In the past two years, Bluejay Diagnostics (BJDX) has reported FDA regulatory activity for Interleukin-6. What is the most recent FDA event for Bluejay Diagnostics? The most recent FDA-related event for Bluejay Diagnostics occurred on April 7, 2026, involving Interleukin-6. The update was categorized as "Enrollment Update," with the company reporting: "Bluejay Diagnostics, Inc. announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring." What conditions do Bluejay Diagnostics' current drugs treat? Currently, Bluejay Diagnostics has one therapy (Interleukin-6) targeting the following condition: In patients diagnosed with sepsis and septic shock.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsBelite Bio FDA EventsDogwood Therapeutics FDA EventsDyne Therapeutics FDA EventsEikon Therapeutics FDA EventsGreenwich LifeSciences FDA EventsHarrow FDA EventsImmunome FDA EventsOncolytics Biotech FDA EventsOric Pharmaceuticals FDA EventsScholar Rock FDA EventsBiohaven FDA EventsNuvation Bio FDA Events4D Molecular Therapeutics FDA EventsREGENXBIO FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies PAVmed FDA Events Intelligent Bio Solutions FDA Events Aethlon Medical FDA Events Valion Bio, Inc. Common Stock FDA Events Lyra Therapeutics FDA Events Strata Skin Sciences FDA Events Nuwellis FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:BJDX last updated on 4/7/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Enrollment Update - April 7,2026Enrollment Update Drug: Interleukin-6Announced Date: April 7, 2026Indication: In patients diagnosed with sepsis and septic shock.AnnouncementBluejay Diagnostics, Inc. announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring.Read Announcement
Abstract Presentation - April 15,2025Abstract Presentation Drug: Interleukin-6Announced Date: April 15, 2025Indication: In patients diagnosed with sepsis and septic shock.AnnouncementBluejay Diagnostics, Inc. announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025.AI SummaryBluejay Diagnostics, Inc. announced that an abstract detailing the Symphony IL-6 Test, its lead product candidate, has been accepted for presentation at the SAEM Annual Meeting in Philadelphia from May 13-16, 2025. This abstract is based on the SYMON-I pilot clinical study, which examines the role of interleukin‑6 (IL‑6) in sepsis patients. The study assessed IL‑6 levels as an early indicator to predict 28-day and 7-day mortality rates, as well as microbiological outcomes. The upcoming presentation will allow emergency medicine professionals to gain insights into how the Symphony IL‑6 Test could serve as a valuable tool for early diagnosis and management of sepsis. This development marks a significant step forward in deploying rapid biomarker testing in the clinical setting, aiming to improve patient triage and care in critical situations.Read Announcement
